EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies : 2023 update. / Gossec, Laure; Kerschbaumer, Andreas; Ferreira, Ricardo J. O.; Aletaha, Daniel; Baraliakos, Xenofon; Bertheussen, Heidi; Boehncke, Wolf-Henning; Esbensen, Bente Appel; McInnes, Iain B.; McGonagle, Dennis; Winthrop, Kevin L; Balanescu, Andra; Balint, Peter V; Burmester, Gerd R.; Cañete, Juan D.; Claudepierre, Pascal; Eder, Lihi; Hetland, Merete Lund; Iagnocco, Annamaria; Kristensen, Lars Erik; Lories, Rik; Queiro, Rubén; Mauro, Daniele; Marzo-Ortega, Helena; Mease, Philip J.; Nash, Peter; Wagenaar, Wendy; Savage, Laura; Schett, Georg; Shoop-Worrall, Stephanie J.W.; Tanaka, Yoshiya; Van Den Bosch, Filip E.; van der Helm-van Mil, Annette; Zabotti, Alen; van der Heijde, Désirée; Smolen, Josef S.
I: Annals of the Rheumatic Diseases, Bind 83, Nr. 6, 2024, s. 706-719.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies
T2 - 2023 update
AU - Gossec, Laure
AU - Kerschbaumer, Andreas
AU - Ferreira, Ricardo J. O.
AU - Aletaha, Daniel
AU - Baraliakos, Xenofon
AU - Bertheussen, Heidi
AU - Boehncke, Wolf-Henning
AU - Esbensen, Bente Appel
AU - McInnes, Iain B.
AU - McGonagle, Dennis
AU - Winthrop, Kevin L
AU - Balanescu, Andra
AU - Balint, Peter V
AU - Burmester, Gerd R.
AU - Cañete, Juan D.
AU - Claudepierre, Pascal
AU - Eder, Lihi
AU - Hetland, Merete Lund
AU - Iagnocco, Annamaria
AU - Kristensen, Lars Erik
AU - Lories, Rik
AU - Queiro, Rubén
AU - Mauro, Daniele
AU - Marzo-Ortega, Helena
AU - Mease, Philip J.
AU - Nash, Peter
AU - Wagenaar, Wendy
AU - Savage, Laura
AU - Schett, Georg
AU - Shoop-Worrall, Stephanie J.W.
AU - Tanaka, Yoshiya
AU - Van Den Bosch, Filip E.
AU - van der Helm-van Mil, Annette
AU - Zabotti, Alen
AU - van der Heijde, Désirée
AU - Smolen, Josef S
N1 - Publisher Copyright: © European Alliance of Associations for Rheumatology, EULAR 2024. Re-use permitted under CC BY-NC-ND. No commercial re-use. No derivatives. See rights and permissions. Published by BMJ on behalf of EULAR.
PY - 2024
Y1 - 2024
N2 - Objective: New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA. Methods: Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence and grades of recommendations were determined. Results: The updated recommendations comprise 7 overarching principles and 11 recommendations, and provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs should be used in monotherapy only for mild PsA and in the short term; oral glucocorticoids are not recommended. In patients with peripheral arthritis, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended and methotrexate preferred. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drug (bDMARD) should be initiated, without preference among modes of action. Relevant skin psoriasis should orient towards bDMARDs targeting interleukin (IL)-23p40, IL-23p19, IL-17A and IL-17A/F inhibitors. In case of predominant axial or entheseal disease, an algorithm is also proposed. Use of Janus kinase inhibitors is proposed primarily after bDMARD failure, taking relevant risk factors into account, or in case bDMARDs are not an appropriate choice. Inflammatory bowel disease and uveitis, if present, should influence drug choices, with monoclonal tumour necrosis factor inhibitors proposed. Drug switches and tapering in sustained remission are also addressed. Conclusion: These updated recommendations integrate all currently available drugs in a practical and progressive approach, which will be helpful in the pharmacological management of PsA.
AB - Objective: New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA. Methods: Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence and grades of recommendations were determined. Results: The updated recommendations comprise 7 overarching principles and 11 recommendations, and provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs should be used in monotherapy only for mild PsA and in the short term; oral glucocorticoids are not recommended. In patients with peripheral arthritis, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended and methotrexate preferred. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drug (bDMARD) should be initiated, without preference among modes of action. Relevant skin psoriasis should orient towards bDMARDs targeting interleukin (IL)-23p40, IL-23p19, IL-17A and IL-17A/F inhibitors. In case of predominant axial or entheseal disease, an algorithm is also proposed. Use of Janus kinase inhibitors is proposed primarily after bDMARD failure, taking relevant risk factors into account, or in case bDMARDs are not an appropriate choice. Inflammatory bowel disease and uveitis, if present, should influence drug choices, with monoclonal tumour necrosis factor inhibitors proposed. Drug switches and tapering in sustained remission are also addressed. Conclusion: These updated recommendations integrate all currently available drugs in a practical and progressive approach, which will be helpful in the pharmacological management of PsA.
KW - Biological Therapy
KW - Biosimilar Pharmaceuticals
KW - Psoriatic Arthritis
KW - Treatment
U2 - 10.1136/ard-2024-225531
DO - 10.1136/ard-2024-225531
M3 - Journal article
C2 - 38499325
AN - SCOPUS:85188577159
VL - 83
SP - 706
EP - 719
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
IS - 6
ER -
ID: 388940804